From Germ Cell Histogenesis to Precision Risk Stratification: Prognostic and Predictive Molecular Markers in Testicular Germ Cell Tumors-A Systematic Review.
- 1Department of Morphofunctional Sciences I, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
- 2Faculty of Veterinary Medicine, Ion Ionescu de la Brad University of Life Sciences, Aleea Mihail Sadoveanu No. 3, 700490 Iasi, Romania.
Abstract
Background/Objectives: Testicular germ cell tumors (TGCTs) represent the most common solid malignancies in young adult men, with cure rates exceeding 95% under modern cisplatin-based therapy, yet a clinically relevant subset of patients still experiences treatment failure or long-term toxicity. This systematic review synthesizes peer-reviewed evidence, from database inception through 6 July 2026, on prognostic and predictive molecular markers in developmental and endocrine-sensitive testicular carcinogenesis. Methods: A PRISMA 2020-aligned search of MEDLINE/PubMed, Embase, Web of Science Core Collection, and the Cochrane Library was supplemented by registry-based evidence, reference-list screening, and contemporary guidelines to capture diagnostic, prognostic, and predictive biomarkers in TGCTs. The strategy encompassed classical serum markers, tissue-based molecular and immunohistochemical markers, miRNA/cfDNA liquid-biopsy assays, immune and resistance-related features, and validated clinicopathological risk models. Results: The review integrates classical serum biomarkers, pluripotency transcription factors, surface and oncofetal antigens, yolk-sac and trophoblastic markers, circulating microRNAs, methylated cell-free DNA, immune features, and updated clinicopathological risk models. Markers are graded as established, validated research, or emerging candidates. miR-371a-3p shows a high accuracy for active non-teratomatous TGCT, with pooled sensitivity of about 0.90 and specificity of approximately 0.86, but is negative in pure teratoma. AFP, β-hCG, and LDH are still required for staging and IGCCCG risk assignment. Conclusions: Despite the growing promise of biomarker-driven approaches in TGCT, no single serum, tissue, liquid-biopsy, immune, or resistance-associated marker has yet demonstrated sufficient clinical utility to replace comprehensive evaluation based on morphology, staging, histology, imaging, standard serum markers, and established clinicopathological risk assessment.
Related
- Circulating calprotectin and S100A8/A9-related biomarkers for diagnosis and prognostic stratification in adult acute infection and sepsis: a systematic review and meta-analysis.
- Predictive and Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Diabetic Nephropathy: Protocol for a Systematic Review and Meta-Analysis
- Global burden inequality in lifetime risk of penile, prostate, and testicular cancers: a population-based systematic analysis of GLOBOCAN 2022
- Incremental Value of Radiation Dose for Prognostic Stratification Beyond Performance Status in Palliative Radiation Therapy for Bone Metastases
- Fractional tumor burden refines prognostic stratification beyond MGMT status in glioblastoma after chemoradiotherapy
BibTeX
@article{cutitaru2026from,
title = {{From Germ Cell Histogenesis to Precision Risk Stratification: Prognostic and Predictive Molecular Markers in Testicular Germ Cell Tumors-A Systematic Review.}},
author = {Andrei Bogdan Cutitaru and Irina Draga Caruntu and Raluca Anca Balan and Carmen Solcan and Cornelia Amalinei},
journal = {Medical sciences (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/medsci14060633},
url = {https://europepmc.org/article/MED/42930552},
note = {CC BY},
}
RIS
TY - JOUR
TI - From Germ Cell Histogenesis to Precision Risk Stratification: Prognostic and Predictive Molecular Markers in Testicular Germ Cell Tumors-A Systematic Review.
AU - Andrei Bogdan Cutitaru
AU - Irina Draga Caruntu
AU - Raluca Anca Balan
AU - Carmen Solcan
AU - Cornelia Amalinei
PY - 2026
DA - 2026/10/02
JO - Medical sciences (Basel, Switzerland)
DO - 10.3390/medsci14060633
UR - https://europepmc.org/article/MED/42930552
AB - Background/Objectives: Testicular germ cell tumors (TGCTs) represent the most common solid malignancies in young adult men, with cure rates exceeding 95% under modern cisplatin-based therapy, yet a clinically relevant subset of patients still experiences treatment failure or long-term toxicity. This systematic review synthesizes peer-reviewed evidence, from database inception through 6 July 2026, on prognostic and predictive molecular markers in developmental and endocrine-sensitive testicular carcinogenesis. Methods: A PRISMA 2020-aligned search of MEDLINE/PubMed, Embase, Web of Science Core Collection, and the Cochrane Library was supplemented by registry-based evidence, reference-list screening, and contemporary guidelines to capture diagnostic, prognostic, and predictive biomarkers in TGCTs. The strategy encompassed classical serum markers, tissue-based molecular and immunohistochemical markers, miRNA/cfDNA liquid-biopsy assays, immune and resistance-related features, and validated clinicopathological risk models. Results: The review integrates classical serum biomarkers, pluripotency transcription factors, surface and oncofetal antigens, yolk-sac and trophoblastic markers, circulating microRNAs, methylated cell-free DNA, immune features, and updated clinicopathological risk models. Markers are graded as established, validated research, or emerging candidates. miR-371a-3p shows a high accuracy for active non-teratomatous TGCT, with pooled sensitivity of about 0.90 and specificity of approximately 0.86, but is negative in pure teratoma. AFP, β-hCG, and LDH are still required for staging and IGCCCG risk assignment. Conclusions: Despite the growing promise of biomarker-driven approaches in TGCT, no single serum, tissue, liquid-biopsy, immune, or resistance-associated marker has yet demonstrated sufficient clinical utility to replace comprehensive evaluation based on morphology, staging, histology, imaging, standard serum markers, and established clinicopathological risk assessment.
SN - 2076-3271
ER -